SI1873166T1 - IZBOLJĹ ANI sgp 130Fc DIMERJI - Google Patents

IZBOLJĹ ANI sgp 130Fc DIMERJI

Info

Publication number
SI1873166T1
SI1873166T1 SI200630827T SI200630827T SI1873166T1 SI 1873166 T1 SI1873166 T1 SI 1873166T1 SI 200630827 T SI200630827 T SI 200630827T SI 200630827 T SI200630827 T SI 200630827T SI 1873166 T1 SI1873166 T1 SI 1873166T1
Authority
SI
Slovenia
Prior art keywords
dimers
sgp
improved
dimer
molecules
Prior art date
Application number
SI200630827T
Other languages
English (en)
Inventor
Georg Watzig
Dirk Seegert
Original Assignee
Conaris Res Inst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Inst Ag filed Critical Conaris Res Inst Ag
Publication of SI1873166T1 publication Critical patent/SI1873166T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SI200630827T 2006-06-30 2006-06-30 IZBOLJĹ ANI sgp 130Fc DIMERJI SI1873166T1 (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06013668A EP1873166B1 (en) 2006-06-30 2006-06-30 Improved sgp 130Fc dimers

Publications (1)

Publication Number Publication Date
SI1873166T1 true SI1873166T1 (sl) 2011-01-31

Family

ID=37654867

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630827T SI1873166T1 (sl) 2006-06-30 2006-06-30 IZBOLJĹ ANI sgp 130Fc DIMERJI

Country Status (21)

Country Link
US (3) US8895012B2 (sl)
EP (1) EP1873166B1 (sl)
JP (1) JP5417171B2 (sl)
KR (1) KR101474817B1 (sl)
CN (1) CN101484472B (sl)
AT (1) ATE480568T1 (sl)
AU (1) AU2007263939B2 (sl)
BR (1) BRPI0713063B8 (sl)
CA (1) CA2656440C (sl)
CY (1) CY1110973T1 (sl)
DE (1) DE602006016765D1 (sl)
DK (1) DK1873166T3 (sl)
EA (1) EA015620B1 (sl)
ES (1) ES2352561T3 (sl)
HR (1) HRP20100663T1 (sl)
PL (1) PL1873166T3 (sl)
PT (1) PT1873166E (sl)
RS (1) RS51544B (sl)
SI (1) SI1873166T1 (sl)
UA (1) UA95636C2 (sl)
WO (1) WO2008000516A2 (sl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2352561T3 (es) 2006-06-30 2011-02-21 Conaris Research Institute Ag Dímeros de sgp 130fc mejorados.
CA2690825C (en) 2007-05-11 2019-02-12 Altor Bioscience Corporation Fusion molecules and il-15 variants
EP2050759A1 (en) * 2007-10-19 2009-04-22 CONARIS research institute AG Soluble gp 130 muteins with improved binding activity
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
DK2918607T3 (en) * 2010-09-21 2018-01-08 Altor Bioscience Corp MULTIMERIC IL-15 SOLUBLE MUSCLE MOLECULES AND PROCEDURES FOR PRODUCING AND USING THEREOF
CN106851720B (zh) * 2013-09-20 2020-12-11 英特尔公司 Ap位置查询的装置、方法和存储介质
ES2899890T3 (es) 2014-06-30 2022-03-15 Altor Bioscience Corp Moléculas basadas en IL-15 y métodos de uso de las mismas
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
PT3226888T (pt) 2014-12-01 2021-06-02 Ferring Bv Administração de um inibidor seletivo da trans-sinalização de il-6
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP6987424B2 (ja) 2016-05-11 2022-01-05 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを洗浄および／または消毒する方法
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
AU2017345791B2 (en) 2016-10-21 2020-10-22 Altor Bioscience Corporation Multimeric IL-15-based molecules
CN108593912A (zh) * 2018-04-09 2018-09-28 北京大学深圳研究生院 一种可溶性cd38浓度的检测方法
CN108318689A (zh) * 2018-04-09 2018-07-24 北京大学深圳研究生院 一种多发性骨髓瘤的诊断方法
CA3186146A1 (en) 2020-06-10 2021-12-16 Ferring B.V. Pharmaceutical compound for the treatment of atherosclerotic cardiovascular disease
WO2022139580A1 (en) 2020-12-22 2022-06-30 Ferring B.V. Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases
WO2023028654A1 (en) * 2021-09-01 2023-03-09 Telix International Pty Ltd Aggregate separation method
WO2024011946A1 (en) * 2022-07-12 2024-01-18 I-Mab Biopharma (Hangzhou) Co., Ltd Polypeptide dimers for the treatment of systemic sclerosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
EP1060194A1 (en) * 1998-02-25 2000-12-20 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
DE19941897B4 (de) 1999-09-02 2006-06-14 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen
WO2001058957A2 (en) * 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
DK1148065T3 (da) * 2000-04-21 2008-04-28 Conaris Res Inst Ag Fusionsproteiner omfattende to oplöselige gp130-molekyler
CN101045166A (zh) 2001-05-21 2007-10-03 耐科塔医药公司 化学修饰胰岛素的肺部给药
EP1406929A2 (en) * 2001-07-18 2004-04-14 MERCK PATENT GmbH Glycoprotein vi fusion proteins
US6887687B2 (en) * 2001-07-30 2005-05-03 Immunex Corporation Nucleic acids encoding human ataxin-1-like polypeptide IMX97018
PT1641483E (pt) * 2003-06-12 2008-04-29 Lilly Co Eli Proteínas de fusão
EP1491554A1 (en) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
ES2387028T3 (es) * 2003-12-31 2012-09-12 Merck Patent Gmbh Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada
EP1630232B1 (en) 2004-08-27 2008-07-02 CONARIS research institute AG Optimized nucleotide sequences encoding sgp130
EP1801121A1 (en) * 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
ES2352561T3 (es) 2006-06-30 2011-02-21 Conaris Research Institute Ag Dímeros de sgp 130fc mejorados.

Also Published As

Publication number Publication date
KR20090037898A (ko) 2009-04-16
US20140178378A1 (en) 2014-06-26
US9573989B2 (en) 2017-02-21
ES2352561T3 (es) 2011-02-21
AU2007263939A1 (en) 2008-01-03
PT1873166E (pt) 2010-12-09
JP5417171B2 (ja) 2014-02-12
BRPI0713063A2 (pt) 2012-04-17
EA200802396A1 (ru) 2009-06-30
BRPI0713063B8 (pt) 2021-05-25
ATE480568T1 (de) 2010-09-15
DK1873166T3 (da) 2010-12-20
US20150361157A1 (en) 2015-12-17
PL1873166T3 (pl) 2011-03-31
RS51544B (en) 2011-06-30
JP2009540843A (ja) 2009-11-26
US8895012B2 (en) 2014-11-25
EA015620B1 (ru) 2011-10-31
CY1110973T1 (el) 2015-06-11
BRPI0713063B1 (pt) 2019-10-08
EP1873166B1 (en) 2010-09-08
WO2008000516A2 (en) 2008-01-03
UA95636C2 (en) 2011-08-25
KR101474817B1 (ko) 2014-12-22
CN101484472A (zh) 2009-07-15
CN101484472B (zh) 2013-07-24
CA2656440A1 (en) 2008-01-03
CA2656440C (en) 2018-10-02
EP1873166A1 (en) 2008-01-02
US20100028367A1 (en) 2010-02-04
HRP20100663T1 (hr) 2011-01-31
DE602006016765D1 (de) 2010-10-21
AU2007263939B2 (en) 2011-11-24
US9034817B2 (en) 2015-05-19
WO2008000516B1 (en) 2008-05-08
WO2008000516A3 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
SI1873166T1 (sl) IZBOLJĹ ANI sgp 130Fc DIMERJI
DK1347730T3 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
NO20015584D0 (no) Lantidsvarende insulintrofiske peptider
ATE294817T1 (de) Concatamere immunadhäsion
WO2008081701A1 (ja) Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物
PE20091405A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
CA2648109A1 (en) Combination of an anti-ed-b fibronectin domain antibody-il-2 fusion protein and gemcitabine
WO2005001038A3 (en) Recombinant anti-cd30 antibodies and uses thereof
EA200700213A1 (ru) Терапевтические композиции с нейротоксином ботулина
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
UA106869C2 (uk) Поліпептид ace2
ATE485386T1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
HK1121468A1 (en) Synthetic mecp2 sequence for protein substitution therapy
BRPI0720879B8 (pt) microvesícula derivada de levedura carreadora de fator tissular (tf), composição e composição farmacêutica que a compreende e processos para a sua fabricação
CY1109631T1 (el) Χρησιμοποιηση πεπτιδιων, τα οποια εχουν παραχθει απο την αα- ή ββ-αλυσιδα του ανθρωπινου ινωδογονου, για τη θεραπεια σοκ
WO2012078761A3 (en) Dimeric molecular complexes with free cysteine residues and conjugates thereof
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
WO2002048180A3 (de) Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels
WO2008003707A3 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
WO2008062158A3 (en) Polypeptide monomers and dimers containing mutated ilt
WO2008015344A3 (fr) Composition dermatologique et/ou cosmetique contenant des polypeptides ou des peptides issus de la proteine slc24a5
ATE492637T1 (de) An die lck-sh3 und hck-sh3 domäne bindende peptide
BRPI0403173A (pt) polipeptìdeo, molécula de ácido nucleico, vetor, método para preparar um polipeptìdeo, célula, uso do polipeptìdeo e/ou ácido nucleico e/ou do vetor, composição farmacêutica, e, método de tratamento de um paciente humano ou animal